A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
And you have 6 codons to chose from.
-
Correct. Key here too is that if you were to 'optimize' the FCS sequence (as is commonly done for these types ofexperiments) you would _not_ end up with the FCS sequence we see, including the CGG codons. But again, itdoesn't really tell us much.
-
What I think we have to look _very_ closely at are all the specific sites they talk about in the grant and then compare across our alignments - is SC2 unique in those positions compared to, say, the BANAL viruses? Does it flip back toSARS1 at some of these positions, etc.
-
Yup.
-
2021-09-21 08:27
Kristian G. Andersen
I'll get some of this started later today - it's important to get the insights irrespective of what it's going to end upshowing.
-
Would there be any reason to pick the SARS2 backbone for doing these? Assuming they had the genome sequence way back at the start?
-
Well, in the grant they specifically talk about *new* viruses - so a SC2 precursor could have been one of those "low risk" viruses they talk about and then they started fiddling with it.
-
They would have selected it from candidates by genome sequencing it. I guess they would have seen an ACE-2 binding RBD and thought that is the one to try an FCS in?
-
Or they just were selecting viruses by seeing if they could get any to culture and then worry about genome sequencing?